Bergenin, a bioactive compound from Bergenia purpurascens, ameliorates psoriasis by targeting γδT17 cells via PPARγ-mediated PROX1 ubiquitination and degradation
Phytomedicine · 2026-07 · 157 · 158293
DOI: 10.1016/j.phymed.2026.158293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2026-07. Verfasst von Haochang Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, 639 Long Mian Avenue, Nanjing 211198, China. Hauptthemen laut MEDLINE: Psoriasis, PPAR gamma, Tumor Suppressor Proteins, Benzopyrans. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND Psoriasis, a persistent inflammatory skin ailment, is distinguished by aberrant γδT17 cell activation. The primary active compound in Bergenia purpurascens, bergenin (Ber), a natural peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, appears to exhibit anti-γδT17 cell activation effects; nevertheless, its therapeutic efficacy for psoriasis remains to be elucidated. PURPOSE To investigate the effects of Ber on psoriasis and to explore its anti-psoriatic mechanisms of action. METHODS The effects of Ber activation of PPARγ on psoriasis and its γδT17 cells were assessed both in vitro and in vivo. The PPARγ and γδT17 cells activation in psoriatic patients and an imiquimod-induced C57BL/6 mouse model were evaluated. The fatty acid oxidation (FAO) was examined, and prospero homeobox protein 1 (PROX1) degradation and its impact on IL17A transcription were determined by Seahorse metabolic analysis, Co-IP, and ChIP-qPCR. RESULTS Ber alleviated psoriatic dermatitis by reducing γδT17 activation in a PPARγ-dependent manner, an effect abolished by adoptive transfer of activated γδT17 cells. Mechanistically, Ber-induced PPARγ activation enhanced its E3 ligase function, promoting K248-linked ubiquitination and degradation of PROX1. This inhibited CPT1-driven FAO, diminished histone H3K9/27 acetylation at the IL17A promoter, and repressed IL-17A production. CONCLUSION Ber exerts anti-psoriatic effects by activating PPARγ to prompt ubiquitin-mediated PROX1 degradation, thereby inhibiting FAO and IL-17A in γδT17 cells. This finding provides a novel pharmacological mechanism in support of the potential of Ber as a natural therapeutic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, 639 Long Mian Avenue, Nanjing 211198, China.
- Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, 639 Long Mian Avenue, Nanjing 211198, China. Electronic address: yfxiacpu@126.com.
- Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, 639 Long Mian Avenue, Nanjing 211198, China. Electronic address: yuedaicpu@cpu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lin, H., Guo, Y., Wan, X., He, Y., Zhu, Y., Wei, Z., Xia, Y., & Dai, Y. (2026). Bergenin, a bioactive compound from Bergenia purpurascens, ameliorates psoriasis by targeting γδT17 cells via PPARγ-mediated PROX1 ubiquitination and degradation. Phytomedicine, 157, 158293. https://doi.org/10.1016/j.phymed.2026.158293
Vancouver
Lin H, Guo Y, Wan X, He Y, Zhu Y, Wei Z, et al. Bergenin, a bioactive compound from Bergenia purpurascens, ameliorates psoriasis by targeting γδT17 cells via PPARγ-mediated PROX1 ubiquitination and degradation. Phytomedicine. 2026;157:158293. doi:10.1016/j.phymed.2026.158293
BibTeX
@article{Lin2026,
author = {Lin, Haochang and Guo, Yilei and Wan, Xuanming and He, Yue and Zhu, Yanrong and Wei, Zhifeng and Xia, Yufeng and Dai, Yue},
title = {Bergenin, a bioactive compound from Bergenia purpurascens, ameliorates psoriasis by targeting γδT17 cells via PPARγ-mediated PROX1 ubiquitination and degradation},
journal = {Phytomedicine},
year = {2026},
volume = {157},
pages = {158293},
doi = {10.1016/j.phymed.2026.158293}
}
EUVIMED